Sign In
Buy EXAS
$104.91
+0 (+0%)
At Close: Jun 03, 2026
Exact Sciences Corporation (EXAS) Jefferies London Healthcare Conference (Transcript)
04:07pm, Tuesday, 19'th Nov 2024
Exact Sciences Corporation (NASDAQ:EXAS ) Jefferies London Healthcare Conference November 19, 2024 6:00 AM ET Company Participants Kevin Conroy - Chairman and CEO Aaron Bloomer - Chief Financial Offic
EXAS Stock Set to Benefit From Favorable Study Data Backing MCED Test
08:10am, Monday, 18'th Nov 2024
Exact Sciences presents new positive evidence backing the development of an MCED test.
Exact Sciences Unveils Data Showing Promise of Multi-Cancer Early Detection at AACR Special Conference on Liquid Biopsy
01:00pm, Wednesday, 13'th Nov 2024
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present three abstracts highlighting significant advancements in
Exact Sciences: Cancer Detection Stalwart's Bad Quarter Resets Its Overgrown Market Cap.
11:39am, Sunday, 10'th Nov 2024
This article updates the investment merits of Exact Sciences following its disappointing Q3, 2024 earnings. Recent approval of an improved version of its lead product will not show up in revenues for
Cologuard Maker Exact Sciences Slashes Outlook as Losses Mount
12:36pm, Wednesday, 06'th Nov 2024
Exact Sciences (EXAS) shares plunged Wednesday after the maker of the Cologuard colon cancer screening test reported widening losses and cut its outlook.
Colorectal Cancer Diagnostic Focused Exact Sciences Stock Plunges On Weak Annual Guidance, Analyst Sees Compelling Long-Term Entry Point
10:13am, Wednesday, 06'th Nov 2024
On Tuesday, Exact Sciences Corp. EXAS reported a third-quarter EPS loss of $0.21, compared to a break-even a year ago, missing the analyst consensus loss estimate of $0.20.
Exact Sciences Stock Down on Q3 Earnings & Revenue Miss, '24 View Cut
08:55am, Wednesday, 06'th Nov 2024
EXAS' third-quarter 2024 top line benefits from broad-based momentum in Cologuard adoption and Oncotype DX's international expansion.
U.S. stock futures were higher this morning, with the Dow futures gaining around 400 points on Wednesday.
Exact Sciences Corporation (EXAS) Q3 2024 Earnings Call Transcript
09:06pm, Tuesday, 05'th Nov 2024
Exact Sciences Corporation (NASDAQ:EXAS ) Q3 2024 Earnings Conference Call November 5, 2024 5:00 PM ET Company Participants Erik Holznecht - Director, Investor Relations Kevin Conroy - Chairman and CE
Exact Sciences Stock Falls 29% On Weak Results, Downbeat Outlook
08:42pm, Tuesday, 05'th Nov 2024
Exact Sciences stock fell sharply Tuesday after the company cut its full-year outlook and posted weaker-than-expected results. The post Exact Sciences Stock Falls 29% On Weak Results, Downbeat Outlook
Exact Sciences (EXAS) Reports Q3 Loss, Lags Revenue Estimates
06:30pm, Tuesday, 05'th Nov 2024
Exact Sciences (EXAS) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to break-even earnings per share a year ago.
3 Large-Cap Stocks to Buy Ahead of Likely Earnings Beat Tuesday
03:01pm, Monday, 04'th Nov 2024
We have narrowed our search to there large-cap stocks set to report results on Tuesday. These are: EXAS, DD and KGC.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
09:56am, Monday, 04'th Nov 2024
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Exact Sciences to Participate in November Investor Conference
06:00am, Friday, 01'st Nov 2024
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the follow
Exact Sciences (EXAS) Moves to Strong Buy: Rationale Behind the Upgrade
01:01pm, Tuesday, 29'th Oct 2024
Exact Sciences (EXAS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
